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Material and Methods: Adult	patients	treated	for	definite	NB	1–10	years	earlier	sup-
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1  | INTRODUC TION
Most	patients	recover	well	after	treated	neuroborreliosis	(NB;	Obel	
et	 al.,	 2018),	 but	 some	 report	 residual	 symptoms	 as	 pain,	 pares-
thesias,	 fatigue,	and	cognitive	deficits	 (Eikeland,	Ljostad,	Mygland,	
Herlofson,	 &	 Lohaugen,	 2012;	 Eikeland,	 Mygland,	 Herlofson,	 &	
Ljostad,	 2011;	 Knudtzen,	 Andersen,	 Jensen,	 &	 Skarphedinsson,	
2017;	Ljøstad	&	Mygland,	2010).	Almost	all	aspects	of	the	phenom-
enon postborreliosis symptoms are debated, including its existence, 
prevalence,	cause,	spectrum,	and	impact	(Halperin,	2017).	In	a	me-
ta-analysis	 of	 34	 studies,	 Dersch,	 Sommer,	 Rauer,	 and	 Meerpohl	
(2016)	found	that	about	28%	of	patients	treated	for	NB	had	residual	
symptoms, most often pain. The prevalence was highest in studies 
using	diffuse	NB	case	definition.	The	authors	debate	whether	 the	
results are biased and if reports of debilitating fatigue and cognitive 
impairment	after	NB	could	“be	an	artifact	of	unspecific	case	defini-
tions in single studies”. It is also of note that several of the included 
studies	did	not	use	validated	and	standardized	outcome	measures.	
For	 future	 studies,	 it	was	 recommended	 to	 apply	 strict	 case	 defi-









All	 departments	 of	Neurology	 in	Norway	were	 invited	 to	 identify	













2.4 | Patient-reported information about 
education level
Questions about education were obtained by reuse of formula-
tions	from	the	Nord-Trøndelag	Health	Study	3	(HUNT3),	which	is	a	
Norwegian	community-based	survey	(Krokstad	et	al.,	2013).










nously	 administered	 antibiotics	or	both,	 and	 for	how	many	weeks	
Conclusions: Results on validated PROM questionnaires measuring fatigue, anxi-
ety,	depression,	self-reported	somatic	symptom	burden,	and	physical	health-related	
quality	 did	 not	 differ	 between	 persons	 treated	 for	 definite	 NB	 1–10	 years	 earlier	
and	reference	scores.	NB-treated	persons	tended	to	report	a	slightly	poorer	mental	
health-related	quality	of	 life	 than	 found	 in	normative	data,	but	when	adjusting	 for	
confounders	the	causative	connection	is	questionable.	Overall,	the	long-term	prog-
nosis	of	definite	NB	seems	to	be	good.
K E Y W O R D S
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(by	ticking	off	1–6).	For	both	questions,	“I	do	not	remember”	was	an	
optional answer.
2.6 | Patient-reported information about 
comorbidity
The	patients	were	 asked	 if	 they	had	ongoing	or	 previous	 any	of	
the following comorbidities: diabetes mellitus, metabolic disease, 
rheumatoid	 arthritis,	 fibromyalgia,	 systemic	 disease	 (sarcoido-
sis,	systemic	 lupus	erythematosus,	or	Sjögren's	syndrome),	other	
musculoskeletal	 disease,	 multiple	 sclerosis,	 Parkinson's	 disease,	
dementia,	 epilepsy,	 stroke,	 polyneuropathy,	 other	 neurological	
diseases, cancer, heart disease, asthma or chronic obstructive lung 
disease, allergy, chronic fatigue syndrome, depression or anxiety, 
other	psychiatric	disease,	celiac	disease,	osteoporosis,	kidney	dis-
ease, other diseases not specified further. If they answered yes to 
one or more, the patients were classified as suffering from comor-
bidity.	A	sum	score	was	provided	by	giving	each	 “yes”	one	point	
(max	score	24).
2.7 | Patient-reported outcome measures (PROMs)
2.7.1 | Fatigue
Fatigue Severity Scale (FSS)	 is	 a	 validated	 questionnaire	 (Krupp,	
LaRocca,	 Muir-Nash,	 &	 Steinberg,	 1989)	 that	 measures	 level	 of	
agreement	 (1–7)	 with	 nine	 statements	 about	 fatigue.	 The	 final	
score	represents	the	mean	value	of	the	nine	items.	Scores	≥	5	are	
regarded	 as	 severe	 fatigue	 (Lerdal,	Wahl,	 Rustøen,	 Hanestad,	 &	
Moum,	2005).
2.7.2 | Somatic symptom burden during the last 
4 weeks
The Patient Health Questionnaire -15 (PHQ-15) is a validated ques-
tionnaire that charts prevalence and intensity of 15 somatic symp-
toms	(stomach	pain,	back	pain,	pain	in	arms/legs/joints,	menstrual	
cramps,	or	other	problems	with	periods	(women	only),	headache,	
chest pain, fainting spells, feeling of heartpounds or race, short-
ness of breath, pain or problems during sexual intercourse, con-





from 0 to 30 for women.
Scores	 5–9	 points,	 10–14	 points,	 and	 15–30	 points	 indicate	
mild, moderate, and severe somatic symptom burden, respectively 
(Zijlema	et	al.,	2013).	We	translated	the	PHQ-15	questionnaire	into	
Norwegian	 based	 on	 the	 Swedish	 version	 (Nordin,	 Palmquist,	 &	
Nordin,	2013).	A	missing	value	for	a	PHQ-15	item	was	replaced	with	
the average value of the other items if the number of missing values 
did	not	exceed	three	items	(n	=	3;	Kroenke	et	al.,	2002).
2.7.3 | Anxiety and depression
Hospital Anxiety and Depression Scale (HADS) is a validated ques-
tionnaire	measuring	symptoms	of	anxiety	and	depression	(Bjelland,	





replaced with the average value of the other items if the number of 
missing	values	did	not	exceed	one	item	in	each	subscore	(n	=	2).
2.7.4 | Health-related quality of life
RAND-36	 is	a	validated	questionnaire	that	measures	health-related	
quality	of	 life	 (Ware,	2000).	 It	consists	of	36	questions	comprising	
eight	multi-item	scales:	mental	health,	vitality,	bodily	pain,	general	
health, social function, physical function, and physical and emotional 





tervals of differences, we used online calculators http://vassa rstats.
net/prop2_ind.html	 (proportions)	and	https://www.socsc	istat	istics.
com/confi	dence	inter	val/Defau	lt4.aspx	 (means).	 Selected	 variables,	











sent to participate in the study, and 258 returned a satisfactorily 
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completed	questionnaire	(228	web-based,	30	paper),	yielding	a	re-
sponse	rate	of	43%.	Of	ethical	reasons	 (lack	of	 informed	consent),	
we could not obtain data from the nonresponders to detect mean-
ingful differences between those who responded and those who did 
not.
Patient characteristics at the time of filling the questionnaire are 
shown in Table 1.
A	 total	 of	 185	NB-treated	 patients	 (71%)	 reported	 to	 have	 at	
least one of the listed comorbidities, of which the most frequently 
reported	were	 other	musculoskeletal	 diseases	 (nonrheumatic,	 not	
fibromyalgia;	17%),	allergy	 (14%),	depression	or	anxiety	 (11%),	and	
other	 not	 defined	 diseases	 (20%).	 Sixty-nine	 persons	 (27%)	 re-
ported diseases often associated with fatigue as multiple sclerosis 
(3),	systemic	disease	sarcoidosis,	systemic	lupus	erythematosus,	or	
Sjögren's	 syndrome	 (4),	 rheumatoid	 arthritis	 (9),	 fibromyalgia	 (10),	
chronic	 fatigue	 syndrome	 (4),	 Parkinson's	 disease	 (1),	 thyroid	 dys-
functions	(22),	or	cancer	(28).	Mean	number	of	reported	comorbidi-
ties	was	1.4	(SD	=	1.3).
Patient-reported	 information	 on	 clinical	 characteristics	 and	
treatment	of	 the	NB	are	shown	 in	Table	2.	Median	CSF	 leukocyte	







than	 in	 Norwegian	 normative	 data,	 but	 when	 removing	 persons	
with	 confounding	 fatigue	 associated	 comorbidities	 (n	 =	 69)	 from	
the analyses, there was no difference between groups. Physical 
health-related	quality	of	life	(RAND-36	PCS),	mean	FSS	score,	pro-





further	 analyze	 this	 finding,	we	 did	 a	 linear	 regression	 and	 found	
that	poorer	mental	health-related	quality	of	life	was	associated	with	
HADS-A	≥	8	 (p	<	 .001),	HADS-D	≥	8	 (p	<	 .001),	and	PHQ-15	≥	10	
(p	=	.024),	but	not	with	sex,	age,	years	since	NB	diagnosis,	education	
level,	 treatment	administration	route,	 treatment	duration,	CSF	cell	
count at diagnosis, burden of symptoms at diagnosis, memory and/or 
concentration	problems	at	diagnosis,	comorbidity,	or	FSS	≥	5.
4  | DISCUSSION
The main results in the present study were that in our group of 258 
Norwegian	patients	treated	for	definite	NB	one	to	ten	years	earlier	
the prevalence of severe fatigue, substantial symptomatic symptom 
burden, anxiety, and depression did not differ from relevant refer-
ence	 groups,	 and	 reported	 physical	 health-related	 quality	 of	 life	
was	similar	to	normative	data.	Mental	health-related	quality	of	 life	
tended	to	be	slightly	poorer	among	NB-treated	patients,	but	was	as-
sociated with anxiety, depression and presence of moderate or se-




enon	 (Halperin,	 2017).	 Some	have	 found	 residual	 symptoms	 in	 up	
to	50%	(Eikeland	et	al.,	2012;	Eikeland	et	al.,	2011;	Knudtzen	et	al.,	
2017;	Ljøstad	&	Mygland,	2010),	while	others	have	found	that	NB	
has	 no	 substantial	 effect	 on	 long-term	 survival,	 health,	 or	 educa-
tional	 and	 social	 functioning	 (Obel	 et	 al.,	 2018).	 Some	 of	 the	 dis-
agreement may be explained by different study designs and poor 
case	definitions	(Dersch	et	al.,	2016).
TA B L E  1   Demographic features of the study population at the 
























Memory and/or concentration problems 75	(29)
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Our study design does not permit any final conclusions or detec-
tion of causal connections, but our results give a substantial contri-
bution to the debate. It is interesting that when we apply strict case 
definition and validated PROMs there seem to be very few residual 
symptoms	1–10	years	after	adequate	treatment	for	NB.
Some	would	 argue	 that	 a	 recruitment	 rate	 of	 43%	might	 have	
caused a selection bias, and that the time from acute disease might 
have caused a recall bias, and that our findings therefore are un-
reliable. In our opinion, this is not a big error source, as one would 
expect both these potential biases to lead to over reporting of com-
plaints rather than under reporting.
Further,	 comparison	with	normative	data	 should	be	done	with	
caution	and	have	several	caveats.	Among	other	things,	the	popula-
tions may differ regarding gender, age, education level, and comor-
bidity, and also regarding cultural conditions, setting, and patient 
expectations.	 Nevertheless,	 the	 comparisons	 can	 express	 trends.	
Another	study	(Eikeland	et	al.,	2011)	using	validated	questionnaires	
have included matched control persons for comparison. They found 
poorer	physical	and	mental	health-related	quality	of	 life,	and	more	
fatigue	 among	NB-treated	persons	 than	 among	 controls,	 but	 case	
definitions	in	this	study	were	less	strict,	as	16/50	(32%)	were	classi-
fied	as	possible	NB.




N = 258 Reference scores
95% CI of the 
difference
Fatigue





FSS	score	≥	5 80	(32%) 0.03 to 0.15
Responders without fatigue associated comorbidities n = 184  
FSS,	mean	(SD) 3.63	(1.84) 0.2 to 0.6
FSS	score	≥	5 50	(27%) −0.02	to	0.11
Anxiety	and	depression
Anxiety	subscore  Data	from	HUNT	2	and	HUNT	3	(Leiknes	et	al.,	2016)  
HADS-A,	mean	(SD) 4.6	(3.7) 4.0	(3.3)	n = 39,277 0.20 to 1.10
HADS-A	score	≥	8 50/257	(19%) 15%	n = 7,014 −0.002	to	0.1
Depression subscore  
HADS-D,	mean	(SD) 3	(3.0) 3.3	(2.9)	n = 39,573 −0.26	to	0.46





PCS,	mean	(SD) 46.5	(9.7) 47.8	(10.7) −0.16	to	2.76




MCS,	mean	(SD) 47.1	(9.9) 48.5	(10.7) 0.03 to 2.77
Somatic symptom load
  Swedish	normative	data	(Nordin	et	al.,	2013)  
PHQ-15,	mean	(SD) All	6.2	(4.7)   
Women	6.8	(4.9) Women	7.2	(4.8)	n = 1,898 −0.702	to	1.102
Men	5.7	(4.3) Men	5.3	(4.4)	n = 1,508 −0.199	to	1.399
PHQ-15	score	≥	10 All	57/245	(23%)   
Women	35/117	(30%) Women	26.4%	n = 1,898 −0.03	to	0.15
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The	mean	 age	 (62	 years)	 in	 our	 cohort	was	 rather	 high,	 and	 a	
substantial	proportion	reported	to	have	comorbidity	(71%),	thus	one	
would expect a certain amount of reported symptoms due to other 
reasons	 than	previous	NB.	Unfortunately,	we	did	not	ask	whether	
the	patients	attributed	their	current	complaints	to	the	previous	NB	
or to other comorbidities. Instead, we adjusted for this confounder 







found in normative data.
Previous prospective studies have found that residual symptoms 
after	treated	NB	is	associated	with	factors	as	pretreatment	symptom	
duration	>	6	weeks,	pretreatment	burden	of	symptoms	and	findings,	
pretreatment	 CSF	 leukocyte	 count,	 and	 female	 gender	 (Eikeland,	
Mygland,	Herlofson,	&	Ljøstad,	2013;	Knudtzen	et	al.,	2017;	Ljøstad	
&	Mygland,	2010).	We	did	not	find	any	association	between	the	only	
PROM	 that	 differed	 between	 NB-treated	 persons	 and	 reference	
data,	namely	mental	health-related	quality	of	 life,	and	pretreatment	





Results on validated PROM questionnaires measuring fatigue, anxi-
ety,	depression,	self-reported	somatic	symptom	burden,	and	physi-
cal	 health-related	 quality	 did	 not	 differ	 between	 persons	 treated	
for	definite	NB	1–10	years	earlier	and	reference	scores.	NB-treated	
persons	 tended	 to	 report	 a	 slightly	 poorer	 mental	 health-related	
quality of life than found in normative data, but when adjusting for 
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